Kenyan-born Turkish distance runner took European cross-country titles in 2016 and 2019 but will now serve a three-year ban for doping
Aras Kaya, a two-time European cross-country champion and Olympian at the Rio Games, has been given a three-year ban for doping after testing positive for erythropoietin (EPO).
The 28-year-old, who was born in Kenya as Amos Kibitok before switching nations to represent Turkey, tested positive at the Brasov Running Festival 10km in Brasov, Romania, in September – a race he failed to finish.
He was given a four-year ban but will only serve three years due to not fighting the case and instead admitting he was at fault.
Kaya won the 2016 Euro Cross senior men’s title by three seconds from Polat Kemboi Arikan in Chia in 2016 with Brits Callum Hawkins, Andy Butchart and Andy Vernon finishing third, fourth and fifth.
In Lisbon in 2019 Kaya finished runner-up to Robel Fsiha although the Swedish winner tested positive the following year and was banned for four years. Yeman Crippa of Italy, who was third in Lisbon, should now be elevated to the gold medal position.
Kaya moved to Turkey in 2015 and got Turkish citizenship in June 2016. He won European 3000m steeplechase silver that summer and competed at the Rio Games for his new country but failed to make it past the steeplechase heats.
Also at the Euro Cross, Kaya won bronze in 2018 and was runner-up to Jakob Ingebrigtsen in 2021.
According to statistics produced for this month’s Euro Cross in Turin, in the last year or so Kaya was reported to have been in the process of receiving Russian nationalisation as he has been based in the Russian city of Kazan.
His track bests include 27:48.53 for 10,000m and a half-marathon PB of 60:51, whereas races this year include finishing third in the European 10,000m Cup, fourth in the Mediterranean Games and 16th at the European Championships at 10,000m.
He was also down to run the Euro Cross in Turin last weekend but not surprisingly – with this doping ban imminent – he was a late withdrawal.
» For more AW news, CLICK HERE
Subscribe to the AW Newsletter